Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Kyu-pyo Kim"'
Autor:
Jae-Lyun Lee, Yong Sang Hong, Jae-Gook Shin, Tae Won Kim, Ho-Sook Kim, Kyun-Seop Bae, Jung Shin Lee, Kyu-Pyo Kim
Publikováno v:
Oncology. 88:164-172
Purpose: A UGT1A1 genotype-directed dose escalation of irinotecan (CPT-11) was performed in patients with metastatic colorectal cancer receiving first-line FOLFIRI chemotherapy. Methods: Patients were genotyped for UGT1A1 and stratified according to
Autor:
Cheolwon Suh, Young Suk Park, Byeong Seok Sohn, Joong Bae Ahn, Sun-Young Kim, Seock-Ah Im, Jeong Eun Kim, Jee Hyun Kim, Kyu Pyo Kim, Yong Sang Hong, Seon-Young Kim, Tae Won Kim, Yong Sung Kim, Seong Joon Park
Publikováno v:
Oncology. 87:280-292
Objective: The aim of this study was to evaluate the association between the efficacy of first-line cytotoxic chemotherapy plus bevacizumab and single-nucleotide polymorphisms (SNPs) of angiogenic genes in patients with advanced colorectal cancer (CR
Autor:
Kyu-Pyo Kim, Min-Hee Ryu, Seong Joon Park, Heung Moon Chang, Yoon-Koo Kang, Yong Sang Hong, Jae-Lyun Lee, Young-Soon Na, Chang Sik Yu, Tae-Won Kim, Dong-Hoon Jin, Jin Cheon Kim, Yong Chel Ahn
Publikováno v:
Oncology. 82:83-89
Objective: The anti-epidermal growth factor receptor monoclonal antibody cetuximab has been shown to be effective in patients with wild-type KRAS metastatic colorectal cancer (mCRC). Fragment C γ receptor (FcγR) polymorphisms may predict the effect
Autor:
Heung Moon Chang, Sung Sook Lee, Ho-Sook Kim, Yoon Choi, Yong Sang Hong, Baek-Yeol Ryoo, Jae-Gook Shin, Tae-Won Kim, Yoon-Koo Kang, Kyu-Pyo Kim, Min-Hee Ryu, Jae-Lyun Lee
Publikováno v:
Oncology. 82:290-297
Objectives: We investigated the efficacy and safety of the combination of irinotecan (CPT-11) and S-1 (IRIS regimen) as a first-line treatment in patients with metastatic colorectal cancer. We also evaluated the association between UGT1A1 and CYP2A6
Autor:
Kyu-Pyo, Kim, Yong Sang, Hong, Jae-Lyun, Lee, Kyun Seop, Bae, Ho-Sook, Kim, Jae-Gook, Shin, Jung Shin, Lee, Tae Won, Kim
Publikováno v:
Oncology. 88(3)
A UGT1A1 genotype-directed dose escalation of irinotecan (CPT-11) was performed in patients with metastatic colorectal cancer receiving first-line FOLFIRI chemotherapy.Patients were genotyped for UGT1A1 and stratified according to the number of defec
Autor:
Jae-Lyun Lee, Yong Sang Hong, Jeong Eun Kim, Seung-Mo Hong, Jin Cheon Kim, Seok-Byung Lim, Kyu-Pyo Kim, In Ja Park, Seong Joon Park, Tae Won Kim, Chang Sik Yu, Chan Wook Kim, Yong Sik Yoon, Dong-Hoon Jin, Seung-Mi Kim
Publikováno v:
Oncology. 88(2)
Objectives: This study investigates the clinical significance of the gene encoding AP-2ε (TFAP2E) in colorectal cancer (CRC) patients undergoing curative resection. Methods: A single-institution cohort of 248 patients who underwent curative resectio
Autor:
Yoon Hee, Choi, Tae Won, Kim, Kyu-Pyo, Kim, Sung Sook, Lee, Yong Sang, Hong, Min-Hee, Ryu, Jae-Lyun, Lee, Heung Moon, Chang, Baek-Yeol, Ryoo, Ho-Sook, Kim, Jae-Gook, Shin, Yoon-Koo, Kang
Publikováno v:
Oncology. 82(5)
We investigated the efficacy and safety of the combination of irinotecan (CPT-11) and S-1 (IRIS regimen) as a first-line treatment in patients with metastatic colorectal cancer. We also evaluated the association between UGT1A1 and CYP2A6 polymorphism
Autor:
Seong Joon, Park, Yong Sang, Hong, Jae-Lyun, Lee, Min-Hee, Ryu, Heung Moon, Chang, Kyu-pyo, Kim, Yong Chel, Ahn, Young-Soon, Na, Dong-Hoon, Jin, Chang Sik, Yu, Jin Cheon, Kim, Yoon-Koo, Kang, Tae Won, Kim
Publikováno v:
Oncology. 82(2)
The anti-epidermal growth factor receptor monoclonal antibody cetuximab has been shown to be effective in patients with wild-type KRAS metastatic colorectal cancer (mCRC). Fragment C γ receptor (FcγR) polymorphisms may predict the effectiveness of
Autor:
Shigeru Marubashi, Seock-Ah Im, Dirk Bauerschlag, Jae Yup Hong, Walter Jonat, Violante Di Donato, Laura Pala, Masayuki Ohue, Druckerei Stückle, Ran-Ju Kim, Hee Jung Ahn, Sun Young Kim, Jee Hyun Kim, Christoph Mundhenke, Domenica Lorusso, Antonia S. Wenners, Yoshiyuki Fujiwara, Satz Mengensatzproduktion, Tae Won Kim, Marion T. Weigel, Masahiko Yano, Cheolwon Suh, Masaaki Motoori, Jeong Eun Kim, Katharina Tiemann, Eunjin Bae, Mathias Muth, Seon-Young Kim, Monika Baier, Cathy Mast, Young Suk Park, Antonella Palazzo, Veronica Bellini, Nicolai Maass, Ramesh K. Ramanathan, Paolo Lisi, Peter Rosen, Italo Sarno, Shingo Noura, Yong Sang Hong, Kyu-Pyo Kim, Young Kwon Hong, Jong Jin Oh, Kentaro Kishi, Nam Keun Kim, Dong Soo Park, Donald I. Feinstein, Leonardo Bianchi, Ibrahim Alkatout, Christian Schem, Byeong Seok Sohn, Keijiro Sugimura, Yong Sung Kim, Sven Hanson, Fritz W. Schaefer, Maret Bauer, Masato Sakon, Alfonso Marchianò, Elena Torrisi, Francesco Raspagliesi, Joong Bae Ahn, Seong Joon Park, Hidenori Takahashi
Publikováno v:
Oncology. 87:320-320